Cycle 2
Out of the 754 patients who reported experiencing side effects in cycle 2, 96.7% of the 396 patients who received responses from their providers containing the messaging templates continued their treatment. Among the 358 patients whose responses did not include messaging templates, 90.2% continued their treatment. A chi squared test of association found the 6.5 percentage point difference was statistically significant (